Bell K L, Loveridge N, Lindsay P C, Lunt M, Garrahan N, Compston J E, Reeve J
Department of Medicine, University of Cambridge, United Kingdom.
J Bone Miner Res. 1997 Aug;12(8):1231-40. doi: 10.1359/jbmr.1997.12.8.1231.
The effects of estrogen suppression on osteonal remodeling in young women was investigated using transiliac biopsies (eight paired biopsies + four single pre; three single post biopsies) taken before and after treatment for endometriosis (6 months) with analogs of gonadotrophin releasing hormone (GnRH). Estrogen withdrawal increased the proportion of Haversian canals with an eroded surface (106%, p = 0.047), a double label (238%, p = 0.004), osteoid (71%, p = 0.002), and alkaline phosphatase (ALP) 116%, p = 0.043) but not those showing tartrate-resistant acid phosphatase (TRAP) activity (p = 0.25) or a single label (p = 0.30). Estrogen withdrawal increased TRAP activity in individual osteoclasts in canals with diameters greater than 50 microns (p = 0.0089) and also the number of osteons with diameters over 250 microns (p = 0.049). ALP activity in individual osteoblasts was increased but not significantly following treatment (p = 0.051). Wall thickness was significantly correlated with osteon diameter (p < 0.001). In a separate group of patients (four pairs + one post biopsy) on concurrent treatment with tibolone, there was no significant increase in the osteon density, cortical porosity, median canal diameter, or the markers of bone formation and resorption. Enzyme activities and numbers of active canals were also not increased with the concurrent treatment, but there was still an increase in the osteon diameter. As previously shown for cancellous bone, estrogen withdrawal increased cortical bone turnover. We have now shown that resorption depth within Haversian systems was also increased with treatment. The enhanced TRAP activity in individual osteoclasts supports the concept that osteoclasts are more active following estrogen withdrawal in agreement with theoretical arguments advanced previously. Understanding the cellular and biochemical mechanisms responsible for increased depth of osteoclast resorption when estrogen is withdrawn may allow the development of new strategies for preventing postmenopausal bone loss.
利用髂骨活检(8对活检样本 + 4个治疗前单样本;3个治疗后单样本),对年轻女性中雌激素抑制对骨单位重塑的影响进行了研究。这些活检样本取自子宫内膜异位症患者接受促性腺激素释放激素(GnRH)类似物治疗(6个月)前后。雌激素撤退增加了具有侵蚀表面的哈弗斯管比例(106%,p = 0.047)、双标记比例(238%,p = 0.004)、类骨质比例(71%,p = 0.002)和碱性磷酸酶(ALP)比例(116%,p = 0.043),但未增加显示抗酒石酸酸性磷酸酶(TRAP)活性的比例(p = 0.25)或单标记比例(p = 0.30)。雌激素撤退增加了直径大于50微米的管腔内单个破骨细胞的TRAP活性(p = 0.0089),也增加了直径超过250微米的骨单位数量(p = 0.049)。治疗后单个成骨细胞的ALP活性增加,但无显著差异(p = 0.051)。骨壁厚度与骨单位直径显著相关(p < 0.001)。在另一组同时接受替勃龙治疗的患者(4对 + 1个治疗后活检样本)中,骨单位密度、皮质孔隙率、中位管腔直径或骨形成与吸收标志物均无显著增加。同时治疗也未增加酶活性和活跃管腔数量,但骨单位直径仍有增加。如先前在松质骨中所示,雌激素撤退增加了皮质骨的骨转换。我们现在表明,治疗后哈弗斯系统内的吸收深度也增加了。单个破骨细胞中增强的TRAP活性支持了这样的概念,即破骨细胞在雌激素撤退后更活跃,这与先前提出的理论观点一致。了解雌激素撤退时破骨细胞吸收深度增加的细胞和生化机制,可能有助于开发预防绝经后骨质流失的新策略。